Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04166396 · ClinicalTrials.gov registry record · Early Phase 1
Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis
A Early Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT04166396: Completed Early Phase 1 study, sponsored by Virginia Commonwealth University.
NCT04166396 is a Early Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04166396, a Early Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this research study is to examine if the use of antioxidant supplements impacts exercise intolerance in people with CF.
Primary Outcome
Sirt1 will be assessed via a standard assay from samples taken from the participant's vein
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Resveratrol
- DRUG NR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2024-07-30 |
| Phase | Early Phase 1 |
What the finished NCT04166396 record still lists
NCT04166396 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04166396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04166396 about?
NCT04166396 is a clinical study titled "Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis". The purpose of this research study is to examine if the use of antioxidant supplements impacts exercise intolerance in people with CF.
What is the current status of trial NCT04166396?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2020-02-17. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT04166396?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Resveratrol (DRUG), NR (DRUG).
Who is sponsoring clinical trial NCT04166396?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04166396's enrollment target sits among peer trials
8 1783rd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI